EMEA-001175-PIP01-11-M04 - paediatric investigation plan
Albiglutide
PIPHuman
Glaxo Group Limited
E-mail: eu.paediatrics-plans@gsk.com
Tel. +1 4388998201
P/0272/2016: EMA decision of 7 October 2016 on the acceptance of a modification of an agreed paediatric investigation plan for albiglutide (Eperzan), (EMEA-001175-PIP01-11-M04)